Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine

Journal of Virology

Volumn 86, Issue 8, 2012, Pages 4082-4090

  Knudsen, Maria L ^a   Mbewe Mvula, Alice ^b   Rosario, Maximillian ^c   Johansson, Daniel X ^a   Kakoulidou, Maria ^a   Bridgeman, Anne ^b   Reyes Sandoval, Arturo ^b   Nicosia, Alfredo ^d,e,f   Ljungberg, Karl ^a   Hanke, Tomáš ^b,c   Liljeström, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d University of Naples ^*

^e CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLADISTICS; CONTROLLED STUDY; DNA VECTOR; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG POTENCY; ELECTROPORATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREACTIVITY; IN VIVO STUDY; INTERMETHOD COMPARISON; LOW DRUG DOSE; MACACA MULATTA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON; SEMLIKI FOREST ALPHAVIRUS; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VACCINIA VIRUS;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DNA, VIRAL; ELECTROPORATION; FEMALE; GENE ORDER; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; MICE; MICE, INBRED BALB C; PLASMIDS; SEMLIKI FOREST VIRUS; T-LYMPHOCYTES; VACCINES, DNA;

ALPHAVIRUS; CHIMPANZEE ADENOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; SEMLIKI FOREST VIRUS; VACCINIA VIRUS ANKARA;

EID: 84861401590     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06535-11     Document Type: Article

References (53)

1. Ahlén G, et al. 2007. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNAuptake, protein expression, inflammation, and infiltration of CD3_ T cells. J. Immunol. 179:4741-4753.
2. Babiuk S, et al. 2004. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J. Biotechnol. 110:1-10.
3. Barry G, et al. 2009. PKR acts early in infection to suppress Semliki Forest virus production and strongly enhances the type I interferon response. J. Gen. Virol. 90:1382-1391.
4. Barry G, et al. 2010. Semliki Forest virus-induced endoplasmic reticulum stress accelerates apoptotic death of mammalian cells. J. Virol. 84:7369-7377.
5. Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljeström P. 1998. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 16:562-565.
6. Betts MR, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-4789.
7. Broderick KE, et al. 2011. Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther. 18:258-265.
8. Davis BS, et al. 2001. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75:4040-4047.
9. Diebold SS, et al. 2009. Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Ther. 16:359-366.
10. Dubensky Jr, TW, et al. 1996. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J. Virol. 70:508-519.
11. Glasgow GM, McGee MM, Sheahan BJ, Atkins GJ. 1997. Death mechanisms in cultured cells infected by Semliki Forest virus. J. Gen. Virol. 78:1559-1563.
12. Hanke T, et al. 1998. Enhancement of MHC class I-restricted peptidespecific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16:439-445.
13. Hanke T, et al. 1999. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:7524-7532.
14. Harari A, et al. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205:63-77.
15. Harari A, et al. 2006. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211:236-254.
16. Hariharan MJ, et al. 1998. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J. Virol. 72: 950-958.
17. Hidmark ÅS, et al. 2005. Early alpha/beta interferon production by myeloid dendritic cells in response to UV-inactivated virus requires viral entry and interferon regulatory factor 3 but not MyD88. J. Virol. 79: 10376-10385.
18. Hirao LA, et al. 2011. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J. Infect. Dis. 203:95-102.
19. Hocknell PK, et al. 2002. Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J. Virol. 76:5565-5580.
20. Huber JP, Farrar JD. 2011. Regulation of effector and memory T-cell functions by type I interferon. Immunology 132:466-474.
21. Kasturi SP, et al. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470:543-547.
22. Koup RA, et al. 2010. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 5:e9015.
23. Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP. 2006. Type I Interferons are essential for the efficacy of replicase-basedDNAvaccines. Vaccine 24:5110-5118.
24. Leitner WW, et al. 2004. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 22:1537-1544.
25. Letourneau S, et al. 2007. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2:e984.
26. Liu MA. 2010. Immunologic basis of vaccine vectors. Immunity 33:504-515.
27. Ljungberg K, et al. 2007. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. J. Virol. 81:13412-13423.
28. Low L, et al. 2009. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum. Gene Ther. 20:1269-1278.
29. McCormack S, et al. 2008. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 26:3162-3174.
30. McInerney GM, Kedersha NL, Kaufman RJ, Anderson P, Liljeström P. 2005. Importance of eIF2alpha phosphorylation and stress granule assembly in alphavirus translation regulation. Mol. Biol. Cell 16:3753-3763.
31. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6:769-776.
32. Näslund TI, Kostic L, Nordström EK, Chen M, Liljeström P. 2011. Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines. Virol. J. 8:36.
33. Nordström EK, et al. 2005. Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type J. Gen. Virol. 86:349-354.
34. Paris RM, Kim JH, Robb ML, Michael NL. 2010. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev. Vaccines 9:1055-1069.
35. Pichlmair A, Reis e Sousa C. 2007. Innate recognition of viruses. Immunity 27:370-383.
36. Rerks-Ngarm S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
37. Roos AK, et al. 2009. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 4:e7226.
38. Roos AK, Eriksson F, Walters DC, Pisa P, King AD. 2009. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol. Ther. 17:1637-1642.
39. Roos AK, et al. 2006. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol. Ther. 13:320-327.
40. Rosario M, et al. 2010. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur. J. Immunol. 40:1973-1984.
41. Sandström E, et al. 2008. Broad immunogenicity of a multigene, multiclade HIV-1DNAvaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198:1482-1490.
42. Schell JB, et al. 2011. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J. Virol. 85:5764-5772.
43. Schneider J, et al. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malariaDNAvaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402.
44. Schulz O, et al. 2005. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433:887-892.
45. Schulz O, et al. 2010. Protein kinase R contributes to immunity against specific viruses by regulating interferon mRNA integrity. Cell Host Microbe 7:354-361.
46. Strauss JH, Strauss EG. 1994. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58:491-562.
47. Takahashi H, et al. 1988. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 85:3105-3109.
48. van Drunen Littel-van den Hurk S, Hannaman D. 2010. Electroporation for DNA immunization: clinical application. Expert Rev. Vaccines 9:503-517.
49. Vasan S, et al. 2011. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 6:e19252.
50. Ventoso I, et al. 2006. Translational resistance of late alphavirus mRNA to eIF2alpha phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev. 20:87-100.
51. Wallace M, et al. 2009. Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults. Mol. Ther. 17:922-928.
52. Wijesundara DK, Jackson RJ, Ramshaw IA, Ranasinghe C. 2011. Human immunodeficiency virus-1 vaccine design: where do we go now? Immunol. Cell Biol. 89:367-374.
53. Xiao Z, Casey KA, Jameson SC, Curtsinger JM, Mescher MF. 2009. Programming for CD8 T cell memory development requires IL-12 or type I IFN. J. Immunol. 182:2786-2794.